Skip to content

Released Nov 12, 2026, after the close

10-Q filed Nov 12, 2026, 43 days after period end · 0001390478-26-000020

Q3 2026 · 10-Q
Revenue$0.00derived— vs Q3 2025no prior Q2 2026 on file
Net Income-$10.09MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.05N/M vs Q3 2025N/M vs Q2 2026
Operating Income-$11,309,000N/M
Operating Cash Flowderived-$5,940,000N/M

What the release said

On November 12, 2026, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2026 and providing a corporate update.

SELLAS reported a net loss of $10.1 million for the third quarter of 2026, or $0.05 per share, compared with a net loss of $6.8 million, or $0.06 per share, for the third quarter of 2025.2

Research and development expenses were $7.0 million and general and administrative expenses were $4.3 million for the third quarter of 2026, compared with $4.2 million and $2.9 million for the same period in 2025.34

Cash and cash equivalents totaled approximately $134.7 million as of September 30, 2026.5

The company expects to announce topline primary endpoint results of the Phase 3 REGAL trial of GPS in November 2026 following the pre-specified 80th event.67

Phase 2 data for tambiciclib (SLS009) in relapsed or refractory AML, showing a 54% ORR in monocytic AML and a 57% ORR in TP53-mutated AML, will be presented at ASH on December 12–15, 2026.8

Net loss, third quarter 2026
$10.1 million Compared with $6.8 million for the third quarter of 20252
Basic and diluted loss per share, third quarter 2026
$0.05 Compared with $0.06 for the third quarter of 20252
Research and development expenses, third quarter 2026
$7.0 million Compared with $4.2 million for the same period in 20253
General and administrative expenses, third quarter 2026
$4.3 million Compared with $2.9 million for the same period in 20254
Cash and cash equivalents
$134.7 million As of September 30, 20265
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$0.00$0.00—$0.00
Net Income-$10.09M-$6.79M-$7.11M-$9.27M
EPS Diluted-$0.05-$0.06-$0.10-$0.33

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR